Literature DB >> 25901434

Factor XI antisense oligonucleotide for venous thrombosis.

Harry R Büller, David Gailani, Jeffrey I Weitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25901434     DOI： 10.1056/NEJMc1503223

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

Review 1.  Antisense technology: an overview and prospectus.

Authors:  Stanley T Crooke; Brenda F Baker; Rosanne M Crooke; Xue-Hai Liang
Journal:  Nat Rev Drug Discov       Date:  2021-03-24       Impact factor: 84.694

2.  Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist.

Authors:  Domenico Girelli; Fabiana Busti; Giacomo Marchi; Nicola Martinelli; Oliviero Olivieri
Journal:  Intern Emerg Med       Date:  2018-03-01       Impact factor: 3.397

3.  Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability.

Authors:  Rami Abu-Fanne; Victoria Stepanova; Rustem I Litvinov; Suhair Abdeen; Khalil Bdeir; Mohamed Higazi; Emad Maraga; Chandrasekaran Nagaswami; Alexander R Mukhitov; John W Weisel; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Blood       Date:  2018-11-15       Impact factor: 22.113

Review 4.  Antisense technology: A review.

Authors:  Stanley T Crooke; Xue-Hai Liang; Brenda F Baker; Rosanne M Crooke
Journal:  J Biol Chem       Date:  2021-02-16       Impact factor: 5.157

5.  Pharmacological reduction of coagulation factor XI reduces macrophage accumulation and accelerates deep vein thrombosis resolution in a mouse model of venous thrombosis.

Authors:  Kelley R Jordan; Cory R Wyatt; Meghan E Fallon; Randy Woltjer; Edward A Neuwelt; Quifang Cheng; David Gailani; Christina Lorentz; Erik I Tucker; Owen J T McCarty; Monica T Hinds; Khanh P Nguyen
Journal:  J Thromb Haemost       Date:  2022-07-18       Impact factor: 16.036

Review 6.  Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy.

Authors:  Bo Bao; Rika Maruyama; Toshifumi Yokota
Journal:  Intractable Rare Dis Res       Date:  2016-08

7.  mTORC1 promotes aging-related venous thrombosis in mice via elevation of platelet volume and activation.

Authors:  Jun Yang; Xuan Zhou; Xiaorong Fan; Min Xiao; Dinghua Yang; Bo Liang; Meng Dai; Lanlan Shan; Jingbo Lu; Zhiqi Lin; Rong Liu; Jun Liu; Liping Wang; Mei Zhong; Yu Jiang; Xiaochun Bai
Journal:  Blood       Date:  2016-06-10       Impact factor: 22.113

8.  Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Anh T P Ngo; Kelley R Jordan; Paul A Mueller; Matthew W Hagen; Stéphanie E Reitsma; Cristina Puy; Alexey S Revenko; Christina U Lorentz; Erik I Tucker; Quifang Cheng; Monica T Hinds; Sergio Fazio; Brett P Monia; David Gailani; András Gruber; Hagai Tavori; Owen J T McCarty
Journal:  J Thromb Haemost       Date:  2021-02-10       Impact factor: 5.824

9.  First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.

Authors:  Bettina Nowotny; Dirk Thomas; Stephan Schwers; Sara Wiegmann; Wolfgang Prange; Ashraf Yassen; Stefanie Boxnick
Journal:  J Thromb Haemost       Date:  2022-05-20       Impact factor: 16.036

Review 10.  Cell Receptor and Cofactor Interactions of the Contact Activation System and Factor XI.

Authors:  Monika Pathak; Bubacarr Gibril Kaira; Alexandre Slater; Jonas Emsley
Journal:  Front Med (Lausanne)       Date:  2018-03-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.